Volume 36, Issue 10, p1295-1482 October 2014
Integrated Partnerships and the Transformation of Pharmaceutical Research and Development
Kenneth I. Kaitin
Published online: October 6, 2014
From where will the life-saving and life-improving medicines of tomorrow come? It is a fair question. There is ample evidence to suggest that the extant model of drug development is yielding too few products, at too high a cost, to sustain the growth of the research-based pharmaceutical industry, long the dominant source of these medicines.1 Moreover, intense global price pressure, competition from generics, increasing regulatory demands, and expiring patents on many top-selling drugs have created a stifling environment for drug developers.